

Skin Cancer including Melanoma: Assessment and Management - Committee Meeting 4

Date: 16th October 2020

Location: Zoom

Minutes: FINAL

Committee members present:		
Andy Molyneux	Committee Chair	Present for all
Christine Parkinson	Medical Oncologist	Present for all
Delia Sworm	Oncology nurse specialist	Present for all
Dharmisha Chauhan	Co-opted Pharmacist	Present for all
Guy Burkill	Radiologist	Present for all
Gillian Godsell	Clinical nurse specialist	Present for all
Howard Peach	Plastic Surgeon	Present for all
Ian James	Lay member	Present for all
John Lear	Dermatologist (Vice Chair)	Present until 12.50
Lynne Jamieson	Histopathologist	Present for all
Myles Smith	General Surgeon	Present until 12.50
Sophie Wilne	Co-opted Paediatric Oncologist	Present from 14.15
Stephen Keohane	Dermatologist	Present until 12.50
Susan Cheetham	Lay member	Present for all

In attendance:		
Steph Armstrong	NICE Technical Analyst, Health Economics	Present for all
Jemma Deane	NICE Information Services	Present for all
Jeremy Dietz	NICE Technical Analyst, Health Economics	Present for all
Brett Doble	NICE Technical Adviser, Health Economics	Present for all
Victoria Axe	NICE Guideline Commissioning Manager	Present from 14.15
Anthony Gildea	NICE Project Manager	Present for all
Thomas Jarratt	NICE Technical Analyst	Present for all
Caroline Mulvihill	NICE Technical Adviser	Present for all

Apologies:

Steve Watkins	Oncologist
Fiona Collier	GP
Sarah Hemington-Gorse	Plastic Surgeon
Saskia Reeken	Clinical Nurse Specialist
Will Bolland	GP

Item 1

- Welcome
- DOIs
- Minutes from the last meeting

Andy Molyneux (the Chair) welcomed the committee members and attendees to the fourth committee meeting of the 'Skin Cancer including Melanoma: Assessment and Management' guideline. Apologies were noted as listed above.

The Chair introduced new committee member Delia Sworm (DS) who had been recruited as an oncology nurse specialist. DS introduced herself and provided the committee with some information on her professional background and expertise on the topic.

Committee members were asked to declare any new interests that had occurred since the last meeting. No new interests were declared.

Item 2

- Review question 2.1

Committee members and clinical leads Guy Burkill (GB) and Steve Keohane (SK) gave two short presentations to the committee on their clinical specialisms in relation to review question 2.1 *methods of staging in melanoma*.

The Chair thanked both members and invited the committee to discuss this review area in-depth.

Thomas Jarratt (TJ) shared a current draft of review protocol 2.1 on his screen and asked the committee for amendments in order to inform the evidence search.

All changes were recorded and the Chair thanked the committee for their contribution.

Item 3

- Review question 1.1

Thomas Jarratt (TJ) presented new evidence and Jeremy Dietz (JD) presented the proposed economic model for review question 1.1 *Role and optimal timing of genetic testing of the tumour after diagnosis for a person with stage 2C-3 melanoma*

The committee discussed the evidence in-depth and provided feedback on data relevant for health economic modelling.

The Chair thanked JD and TJ for their presentations and the committee for their feedback.

Item 4

- Review protocols

The Chair started the afternoon session by introducing Sophie Wilne (SW), paediatric oncologist and co-opted member of the committee. SW introduced herself to the committee and provided some background information on her clinical specialism and interest in the guideline.

Thomas Jarratt (TJ) then presented the remaining review protocols (3.1 – 6.4) for committee sign-off. The committee discussed the protocols in-depth and provided feedback to the NICE team.

The Chair thanked TJ for his presentation and the committee for their feedback.

Item 6

- AOB, summary and next steps

The Chair thanked the committee for their contribution, summarised the main actions from the day and asked if there was any other business.

Caroline Mulvihill from the NICE team updated the committee regarding the Skin Tumours including Melanoma Cancer Service Guidelines. Following discussion of these guidelines at our last committee meeting, NICE has considered their feedback. It has now been agreed that these guidelines will no longer be stood down but will remain on the NICE website as static guidelines.

Committee members asked if the NICE team would disclose the email addresses of all members for them to liaise with each other. The NICE team confirmed it could once it had received consent from all members, including those not present.

The Chair highlighted the date of the next meeting and as there was no further business, he brought the meeting to a close.

Date of next meeting: 23rd November 2020

Location of next meeting: Zoom